Symbols / PBLA
PBLA Chart
About
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 53.89K |
| Enterprise Value | 1.72M | Income | -37.05M | Sales | — |
| Book/sh | -3.74 | Cash/sh | 0.97 | Dividend Yield | — |
| Payout | 0.00% | Employees | 7 | IPO | — |
| P/E | — | Forward P/E | -0.00 | PEG | — |
| P/S | — | P/B | -0.00 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | 0.25 |
| Current Ratio | 0.26 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -34.51 | EPS next Y | -5.66 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-07-23 16:00 | ROA | -229.77% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 4.85M |
| Shs Float | 4.85M | Short Float | 3.07% | Short Ratio | 0.07 |
| Short Interest | — | 52W High | 0.47 | 52W Low | 0.00 |
| Beta | 2.10 | Avg Volume | 3.69K | Volume | 1.01K |
| Target Price | — | Recom | None | Prev Close | $0.01 |
| Price | $0.01 | Change | 47.02% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.01
Latest analyst target
3. DCF / Fair value
$-29.59
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.01
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-08-15 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-06-24 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-05-16 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2024-04-02 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-03-27 | main | Roth MKM | Buy → Buy | $25 |
| 2024-02-05 | main | Roth MKM | Buy → Buy | $25 |
- Panbela Announces 1-for-20 Reverse Stock Split Effective January 18, 2024 - Stock Titan ue, 16 Jan 2024 08
- Panbela Therapeutics Inc (PBLA) Quarterly 10-Q Report - qz.com hu, 14 Nov 2024 08
- Nasdaq to delist Panbela Therapeutics over equity shortfall - Investing.com hu, 07 Mar 2024 08
- Panbela Provides Business Update and Reports Q3 2024 Financial Results - GlobeNewswire hu, 14 Nov 2024 08
- Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday - InvestorPlace ue, 23 Jan 2024 08
- Head-To-Head Survey: Panbela Therapeutics (OTCMKTS:PBLA) and Virios Therapeutics (NASDAQ:VIRI) - Defense World Wed, 25 Feb 2026 06
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| TaxEffectOfUnusualItems | 2.96K | 0.00 | 0.00 |
| TaxRateForCalcs | 0.01 | 0.00 | 0.03 |
| NormalizedEBITDA | -25.53M | -34.76M | -10.61M |
| TotalUnusualItems | 400.00K | 0.00 | 0.00 |
| TotalUnusualItemsExcludingGoodwill | 400.00K | 0.00 | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | -25.26M | -34.93M | -10.13M |
| EBITDA | -25.13M | -34.76M | -10.61M |
| EBIT | -25.13M | -34.76M | -10.61M |
| NetInterestIncome | -194.00K | -274.00K | -11.00K |
| InterestExpense | 317.00K | 288.00K | 12.00K |
| InterestIncome | 123.00K | 14.00K | 1.00K |
| NormalizedIncome | -25.66M | -34.93M | -10.13M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -25.26M | -34.93M | -10.13M |
| TotalExpenses | 25.65M | 34.09M | 10.01M |
| TotalOperatingIncomeAsReported | -25.65M | -34.09M | -10.01M |
| DilutedAverageShares | 108.69K | 1.75K | 560.00 |
| BasicAverageShares | 108.69K | 1.75K | 560.00 |
| DilutedEPS | -316.52 | -19.97K | -18.10K |
| BasicEPS | -316.52 | -19.97K | -18.10K |
| DilutedNIAvailtoComStockholders | -25.26M | -34.93M | -10.13M |
| NetIncomeCommonStockholders | -25.26M | -34.93M | -10.13M |
| NetIncome | -25.26M | -34.93M | -10.13M |
| NetIncomeIncludingNoncontrollingInterests | -25.26M | -34.93M | -10.13M |
| NetIncomeContinuousOperations | -25.26M | -34.93M | -10.13M |
| TaxProvision | -186.00K | -116.00K | -488.00K |
| PretaxIncome | -25.45M | -35.05M | -10.62M |
| OtherIncomeExpense | 392.00K | -682.00K | -602.00K |
| OtherNonOperatingIncomeExpenses | -8.00K | -682.00K | -602.00K |
| SpecialIncomeCharges | 400.00K | 0.00 | 0.00 |
| GainOnSaleOfPPE | 400.00K | 0.00 | |
| NetNonOperatingInterestIncomeExpense | -194.00K | -274.00K | -11.00K |
| InterestExpenseNonOperating | 317.00K | 288.00K | 12.00K |
| InterestIncomeNonOperating | 123.00K | 14.00K | 1.00K |
| OperatingIncome | -25.65M | -34.09M | -10.01M |
| OperatingExpense | 25.65M | 34.09M | 10.01M |
| ResearchAndDevelopment | 20.61M | 28.05M | 5.42M |
| SellingGeneralAndAdministration | 5.03M | 6.04M | 4.59M |
| GeneralAndAdministrativeExpense | 5.03M | 6.04M | 4.59M |
| OtherGandA | 5.03M | 6.04M | 4.59M |
| TotalRevenue | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | ||
|---|---|---|---|
| TreasurySharesNumber | 70.00 | ||
| OrdinarySharesNumber | 480.02K | 1.75K | 560.00 |
| ShareIssued | 480.10K | 1.75K | 560.00 |
| NetDebt | 2.62M | 5.56M | |
| TotalDebt | 5.19M | 6.84M | |
| TangibleBookValue | -4.71M | -8.05M | 10.21M |
| InvestedCapital | 484.00K | -1.21M | 10.21M |
| WorkingCapital | -9.26M | -6.06M | 9.62M |
| NetTangibleAssets | -4.71M | -8.05M | 10.21M |
| CommonStockEquity | -4.71M | -8.05M | 10.21M |
| TotalCapitalization | -516.00K | -2.85M | 10.21M |
| TotalEquityGrossMinorityInterest | -4.71M | -8.05M | 10.21M |
| StockholdersEquity | -4.71M | -8.05M | 10.21M |
| GainsLossesNotAffectingRetainedEarnings | 745.00K | 759.00K | 133.00K |
| OtherEquityAdjustments | 745.00K | 759.00K | 133.00K |
| TreasuryStock | 1.00K | 0.00 | |
| RetainedEarnings | -125.50M | -91.09M | -56.16M |
| AdditionalPaidInCapital | 120.04M | 82.29M | 66.24M |
| CapitalStock | 0.00 | 0.00 | 0.00 |
| CommonStock | 0.00 | 0.00 | 0.00 |
| PreferredStock | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 16.51M | 13.03M | 2.66M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 4.19M | 5.19M | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 4.19M | 5.19M | |
| LongTermDebt | 4.19M | 5.19M | |
| CurrentLiabilities | 12.32M | 7.83M | 2.66M |
| CurrentDebtAndCapitalLeaseObligation | 1.00M | 1.65M | |
| CurrentDebt | 1.00M | 1.65M | |
| OtherCurrentBorrowings | 1.00M | 1.00M | |
| CurrentNotesPayable | 0.00 | 650.00K | 0.00 |
| PensionandOtherPostRetirementBenefitPlansCurrent | 516.00K | 998.00K | 434.00K |
| PayablesAndAccruedExpenses | 10.80M | 5.18M | 2.23M |
| CurrentAccruedExpenses | 863.00K | 2.32M | 1.59M |
| InterestPayable | 238.00K | 325.00K | 0.00 |
| Payables | 9.94M | 2.87M | 640.00K |
| AccountsPayable | 9.94M | 2.87M | 640.00K |
| TotalAssets | 11.80M | 4.98M | 12.87M |
| TotalNonCurrentAssets | 8.74M | 3.20M | 593.00K |
| OtherNonCurrentAssets | 3.20M | 593.00K | |
| NonCurrentPrepaidAssets | 8.74M | 3.20M | |
| CurrentAssets | 3.06M | 1.78M | 12.28M |
| OtherCurrentAssets | 299.00K | 443.00K | 91.00K |
| PrepaidAssets | 91.00K | ||
| Receivables | 183.00K | 49.00K | 321.00K |
| TaxesReceivable | 183.00K | 49.00K | 321.00K |
| CashCashEquivalentsAndShortTermInvestments | 2.58M | 1.28M | 11.87M |
| CashAndCashEquivalents | 2.58M | 1.28M | 11.87M |
| Line Item | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| FreeCashFlow | -25.25M | -15.94M | -7.25M |
| RepurchaseOfCapitalStock | -10.00K | ||
| RepaymentOfDebt | -1.65M | 0.00 | 0.00 |
| IssuanceOfDebt | 0.00 | ||
| IssuanceOfCapitalStock | 23.05M | 5.35M | 9.05M |
| CapitalExpenditure | -660.00K | ||
| InterestPaidSupplementalData | 404.00K | 15.00K | 12.00K |
| EndCashPosition | 2.58M | 1.28M | 11.87M |
| BeginningCashPosition | 1.28M | 11.87M | 9.02M |
| EffectOfExchangeRateChanges | 0.00 | -4.00K | -6.00K |
| ChangesInCash | 1.29M | -10.58M | 2.85M |
| FinancingCashFlow | 26.14M | 5.35M | 10.10M |
| CashFlowFromContinuingFinancingActivities | 26.14M | 5.35M | 10.10M |
| ProceedsFromStockOptionExercised | 4.75M | 5.00K | 1.04M |
| NetCommonStockIssuance | 23.04M | 5.35M | 9.05M |
| CommonStockPayments | -10.00K | ||
| CommonStockIssuance | 23.05M | 5.35M | 9.05M |
| NetIssuancePaymentsOfDebt | -1.65M | 0.00 | 0.00 |
| NetShortTermDebtIssuance | -1.65M | 0.00 | |
| ShortTermDebtPayments | -1.65M | 0.00 | |
| NetLongTermDebtIssuance | 0.00 | ||
| LongTermDebtPayments | 0.00 | ||
| LongTermDebtIssuance | 0.00 | ||
| InvestingCashFlow | 400.00K | -656.00K | 0.00 |
| CashFlowFromContinuingInvestingActivities | 400.00K | -656.00K | 0.00 |
| NetOtherInvestingChanges | -540.00K | ||
| NetBusinessPurchaseAndSale | 0.00 | 4.00K | 0.00 |
| SaleOfBusiness | 0.00 | 4.00K | 0.00 |
| NetIntangiblesPurchaseAndSale | 400.00K | -660.00K | 0.00 |
| SaleOfIntangibles | 400.00K | 0.00 | |
| PurchaseOfIntangibles | 0.00 | -660.00K | 0.00 |
| OperatingCashFlow | -25.25M | -15.28M | -7.25M |
| CashFlowFromContinuingOperatingActivities | -25.25M | -15.28M | -7.25M |
| ChangeInWorkingCapital | -647.00K | 559.00K | 1.60M |
| ChangeInPayablesAndAccruedExpense | 4.88M | 3.04M | 1.84M |
| ChangeInAccruedExpense | -2.18M | 786.00K | 1.21M |
| ChangeInPayable | 7.06M | 2.25M | 631.00K |
| ChangeInAccountPayable | 7.06M | 2.25M | 631.00K |
| ChangeInPrepaidAssets | -5.40M | -2.69M | -293.00K |
| ChangeInReceivables | -132.00K | 212.00K | 51.00K |
| OtherNonCashItems | 238.00K | 273.00K | |
| StockBasedCompensation | 823.00K | 1.09M | 1.29M |
| AssetImpairmentCharge | 0.00 | 17.74M | 0.00 |
| OperatingGainsLosses | -400.00K | ||
| GainLossOnSaleOfPPE | -400.00K | 0.00 | |
| NetIncomeFromContinuingOperations | -25.26M | -34.93M | -10.13M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for PBLA
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|